South Korea is a recognized hub for clinical research in the Asian region, with more clinical trials recorded than any other Asian country between 2001 and 2012.
South Korea is a recognized hub for clinical research in the Asia Pacific region, with more clinical trials recorded than any other Asian country between 2001 and 2017.
There are many government support structures for conducting research in Korea. This, coupled with a sophisticated infrastructure, a large population and a market size of approximately USD 20 billion, Korea attracts a large number of industry sponsors. Strong government support exists to encourage clinical trials in Korea.
Korea is the leading clinical trial destination in the Asian region. Between 2001 and 2012, Korea had the highest number of clinical trials compared to other Asian countries. Approximately 45 % of clinical trials in Korea are multinational trials. There is strong government support to develop Korean clinical trial capacity and capability, and in particular to train clinical trial professionals and develop world-class sites.
The regulatory body responsible for administering the regulatory framework in Korea is the Ministry of Food and Drug Safety (MFDS). The MFDS has a policy of encouraging global trial participation and simultaneous global registration, which is evident from the many government incentives to promote international clinical trials. Only sites accredited by the MFDS may conduct clinical trials. There are more than 180 accredited sites in Korea.
|Official Language||Korean, English (widely taught in junior high and high school)|
|Hospital Records Language||Korean (English commonly used in professional settings)|
|Electronic Hospital Records||Approximately 80% of sites approved for clinical trials have an electronic medical record system. The rest is in the process of transition.|
|Site Network||Only accredited sites are able to carry out human clinical trials. As of August 2017, there are 184 accredited sites in Korea.|
|In-country services||Project Management
|GDP – per capita (US $)||$32,775|
|Health Expenditures||7.2% of GDP|